|
Orthologous residues
|
|
Bim (human): T116‑p, Bim iso2 (human): T56‑p, Bim iso3 (human): ‑, Bim (mouse): T112‑p, Bim (rat): T112‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
2D analysis, mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), MEF (fibroblast)
|
|
Cellular systems studied:
cell lines, primary cells
|
|
Species studied:
human, mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ERK1 (mouse)
|
phospho-antibody, pharmacological activator of upstream enzyme, modification site within consensus motif, pharmacological inhibitor of upstream enzyme
|
|
|
KINASE
|
JNK1 (mouse)
|
phospho-antibody, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme, modification site within consensus motif, genetic knockout/knockin of upstream enzyme
|
|
|
KINASE
|
ERK2 (mouse)
|
phospho-antibody, pharmacological activator of upstream enzyme, modification site within consensus motif, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
serum
|
|
|
|
increase
|
|
|
U0126
|
serum
|
|
|
inhibit treatment-induced increase
|
|
|
UV
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
apoptosis, induced
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
Bcl-2 (mouse)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|